Regarding B, I hope the company doesn't partner B-OM as a solo indication. I am hopeful B matures into 3 silos of deals...

1) Gastrointestinal - OM, UP and everything in between (including Crohn's)
2) Dermatological / Topical (acne, eczema etc. mentioned 2 PR's ago)
3) Antibiotic - ABSSSI, (gateway concept to eye, ears, diabetic foot )

I can easily imagine 3 separate deals in that order.